Scientists Devise Potential Approach to Treat Spinal Muscular Atrophy

Researchers have devised a potential approach to treat the neuromuscular disease spinal muscular atrophy (SMA).

Researchers at Cold Spring Harbor Laboratory (CSHL) and Isis Pharmaceuticals say that they have devised a potential approach to treat the neuromuscular disease spinal muscular atrophy (SMA).

The researchers say that in SMA, a protein deficiency caused by a single gene mutation leads to serious damage in growing nerve cells and the muscles they control.

CSHL professor Dr. Adrian Krainer says that his team has devised a way to induce cells to replenish the protein by activating an existing, slightly modified copy of the mutant gene.

The researchers say that SMA, which affects about one out of every 6,000 newborns, occurs when the baby inherits a defective version of a gene called SMN1 from both its mother and father.

Krainer says that the protein that this gene produces performs cellular "housekeeping" activities, so "it’s hard to explain why it matters more in motor neurons" that are afflicted by SMA than in other cells.

Some SMA patients are affected more profoundly than others, in part because a second version of the gene, SMN2, also produces the protein, and makes up for some of the deficit.

"All these patients, although they’re missing a critical gene, have this second gene that in healthy people is not necessary," says Dr. Krainer.

During the study, the researchers injected promising synthetic molecules called antisense oligonucleotides (ASO) into mice that had an added, human version of the SMN2 gene.

As they had expected, the gene produced much more of the RNA for the critical protein, including the section that is usually omitted, in tissues where the ASOs accumulate.

The researchers say that before this approach can be tried in patients, several additional issues must be addressed-such as whether the ASOs really benefit growing animals with SMA and how and when they should be administered to affect the nervous system.

Still, in contrast to approaches that change splicing patterns for many genes, Krainer expects the highly targeted ASOs may have fewer side effects.

The study appears in the American Journal of Human Genetics.

Source-ANI
SRM/N